Core Insights - The company reported strong first-half 2025 results, achieving a Net Operating Result of EUR 734 million, which is a 20% increase compared to H1 2024 [1] - The positive performance is attributed to a diverse portfolio in Life and Non-Life products, with notable growth in Belgium exceeding 10% and a successful product mix transition in China [1] - The company revised its Elevate27 targets upward, increasing the Holding Free Cash Flow target from above EUR 2.2 billion to more than EUR 2.3 billion by 2027, while maintaining a 6% annual increase in dividend per share [1] Financial Performance - Inflows reached EUR 10.5 billion, representing a 4% increase compared to H1 2024 [1] - The expected Net Operating Result for the full year is projected to be between EUR 1.3 billion and EUR 1.35 billion [1] - Operational capital is expected to be EUR 940 million, reflecting a 17% increase compared to 2024 [1] Shareholder Returns - An interim dividend of EUR 1.50 will be distributed on December 5 [1] - The company plans to distribute over EUR 2 billion to shareholders over the cycle [1] Sustainability Efforts - The company has improved its scores with leading ESG rating agencies, ISS and Sustainalytics, highlighting its commitment to sustainable entrepreneurship [1]